Johnson & Johnson Reports Q1 2023 Results

2023 First-Quarter reported sales growth of 5.6% to $24.7 Billion with operational growth of 9.0%* and adjusted operational growth of 7.6%*



2023 First-Quarter basic loss per share of decreasing... | April 18, 2023

Related Keywords

Joaquin Duato ,Company Consumer Health ,Abiomed ,Consumer Health Company ,Exchange Commission ,Johnson ,Skin Health Beauty ,Interventional Solutions ,Consumer Health ,Chief Executive ,Baby Care ,General Surgery ,Current Reports ,Quarterly Reports ,Annual Reports ,Euro Average Rate ,Private Securities Litigation Reform Act ,New Consumer Health Company ,Annual Report ,Note Regarding Forward Looking ,Consolidated Statement ,Millions Except Per Share Figures ,Millions Except Per Share Data ,Asset Amortization ,Net Earnings ,Medical Device Regulation ,European Medical Devices Directive ,Sales Reconciliation ,Before Tax ,Income Before Tax ,Johnson Stock Exchange ,News ,Information ,Press Release ,023 ,Eported ,Sales ,Growth ,F ,O ,Billion ,Ith ,Perational ,End ,Djusted ,Basic ,Boss ,Her ,Phare ,F Jnj Us4781601046 ,